Liver cancer – pipeline review, h2 2012


Published on

Aarkstore Enterprise-Liver cancer – pipeline review, h2 2012

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Liver cancer – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Liver Cancer – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Liver Cancer - Pipeline Review, Global Markets Direct’s,Liver Cancer - Pipeline Review, H2 2012, provides an overview of the indication’stherapeutic pipeline. This report provides information on the therapeuticdevelopment for Liver Cancer, complete with latest updates, and special features onlate-stage and discontinued projects. It also reviews key players involved in thetherapeutic development for Liver Cancer. Liver Cancer - Pipeline Review, Half Yearis built using data and information sourced from Global Markets Direct’s proprietarydatabases, Company/University websites, SEC filings, investor presentations andfeatured press releases from company/university sites and industry-specific thirdparty sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Liver Cancer.- A review of the Liver Cancer products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.
  2. 2. - Coverage of products based on various stages of development ranging fromdiscovery till registration stages.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Liver Cancer.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 6List of Figures 8Introduction 9Global Markets Direct Report Coverage 9Liver Cancer Overview 10Therapeutics Development 11An Overview of Pipeline Products for Liver Cancer 11Liver Cancer Therapeutics under Development by Companies 13Liver Cancer Therapeutics under Investigation by Universities/Institutes 17Late Stage Products 22Comparative Analysis 22Mid Clinical Stage Products 23Comparative Analysis 23Early Clinical Stage Products 24Comparative Analysis 24Discovery and Pre-Clinical Stage Products 25Comparative Analysis 25Liver Cancer Therapeutics – Products under Development by Companies 26Liver Cancer Therapeutics – Products under Investigation by Universities/Institutes28Companies Involved in Liver Cancer Therapeutics Development 34Bristol-Myers Squibb Company 34F. Hoffmann-La Roche Ltd. 35Eli Lilly and Company 36
  3. 3. Tekmira Pharmaceuticals Corp. 37Bavarian Nordic A/S 38Kowa Company, Ltd. 39List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1 Liver Cancer – Pipeline Review, H2 2012 Non-Small Cell Lung Cancer – Pipeline Review, H2 2012 Asthma – Pipeline Review, H2 2012 Multiple Sclerosis – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012
  4. 4. Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: